ClinicalTrials.gg
CompletedNCT01839773DREAMUpdated Jul 25, 2024

Phase 3 Study to Compare Efficacy and Safety of DHP107 vs. Taxol® in Patients With Metastatic or Recurrent Gastric Cancer

A Phase 3 interventional study of Paclitaxel and Paclitaxel in Stage IV Gastric Cancer, sponsored by Daehwa Pharmaceutical Co., Ltd.. Completed at 13 sites in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-07-25.

Sponsored by Daehwa Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
238
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 92 studies testing paclitaxel in Stomach Neoplasms — 18 open to participants now, 22 under way, 1 of them phase 3. Paclitaxel · Stomach Neoplasms.

Enrollment
10th of 89
238 · median 50
Started
2013
with 2 others
Phase 3
9 of 92
none open now
Registered
25th of 92
by date
Lead sponsor
2 of 92
Daehwa Pharmaceutical Co., Ltd.

Among the 92 studies testing paclitaxel in Stomach Neoplasms, this one is the 10th largest by enrollment of the 89 interventional ones that give a count, is one of 3 that started in 2013, is one of 9 in phase 3, and was the 25th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 993 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

18 of the 92 studies testing paclitaxel in Stomach Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies testing paclitaxel in Stomach Neoplasms, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the efficacy and safety of DHP107 (Oral paclitaxel) in comparison to Taxol®(IV paclitaxel) in Patients With Metastatic or Recurrent Gastric Cancer After Failure of 1st Line Chemotherapy With Fluoropyrimidine +/- Platinum.

03

Conditions studied

  • Stage IV Gastric Cancer

Browse trials for

Keywords

  • Stomach Neoplasms
  • Cancer of Stomach
  • Gastric Cancer
  • Gastric Neoplasms
  • Neoplasms, Gastric
  • Neoplasms, Stomach
  • Stomach Cancer
  • paclitaxel
  • Taxol
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥20 years of age
  2. or cytologically confirmed unresectable, recurrent or gastric cancer
  3. Failure of a therapy with fluoropyrimidine +/- platinum for metastatic or recurrent disease.( chemotherapy is not considered as a first line chemotherapy unless recurrence developed within 6 months of completion of adjuvant therapy.)
  4. Adequate bone marrow, liver and renal functions
  5. ≤ 2.0
  6. performance status ≤ 2
  7. Neuropathy grade ≤ 1
  8. of at least 3 months
  9. according to version 1.1 on CT scan
  10. Written
  11. Patients of child bearing age have to agree to the usage of adequate from before the registration to the study, during the participation period and 90 days after the end of treatment. Female of child bearing age has to show negative for urin pregnancy test within 7 days from beginning of the start of administration. Amenorrhea status has to be sustained for at least 12 months to be considered non-pregnant in case of postmenstrual women.

Exclusion criteria

Exclusion Criteria:

  1. Major infectious disease, neurological disorder, or bowel obstruction.
  2. Patients with (confirmed through brain imaging if there are symptoms)
  3. Patient diagnosed with another cancer type (except non-melanoma skin cancer, cervical cancer, or any other cancer that did not recur or metastasized for more than 5 years and considered as complete remission can be registered)
  4. Patient who received radiation therapy within past 2 weeks or who had major surgery including organ resection within past 4 weeks from random assignment date
  5. Patient with the history of failure to the taxane chemotherapy
  6. Patient who need chronic concomitant use of P glycoprotein, immune suppressor, proton pump inhibitor, or H2-receptor antagonist during the period of clinical trial
  7. Chronic treatment using (except oral, local injection, or for externally applied) or other immune suppressor
  8. Patient with myocardial infarction, congestive heart failure, arrhythmia showing abrupt change in the , severe or unstable angina, or other serious heart disease
  9. Patient with other serious internal disease (chronic obstructive or chronic inhibitory lung disease including shortness of breathe at rest due to all reasons, uncontrollable diabetes and hypertension)
  10. History of abuse of a drug or alcohol within 3 months
  11. Lactating or pregnant women, or patient (or spouse) who has no intension of using, or cannot use very effective mean of
  12. Patient who has or is suspected to have problem in bile acid secretion
  13. Patient with active gastrointestinal bleeding, or taking oral anti- vitamine K (With the exception of low dose of Warfarin and acetylsalicylic acide when ≤2.0)
  14. History of serious hypersensitive reaction to the main ingredient or the of the drug
  15. History of being seropositive for (HIV test is not a prerequisite).
  16. Patients with gastrointestinal dysfunction or on enteral feeding
  17. Other patients who are deemed inadequate to participate in the clinical trial by the investigator
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
238 participants (actual)

Study arms

  • Experimental
    DHP107 (oral paclitaxel)

    DHP107 (oral paclitaxel) will be administered weekly as second line chemotherapy in patients with metastatic or recurrent gastric cancer after failure of first line chemotherapy with fluoropyrimidine +/- platinum.

    Drug: Paclitaxel

  • Active comparator
    Taxol® (IV paclitaxel)

    Taxol® (IV paclitaxel) will be administered 3-weekly as second line chemotherapy in patients with metastatic or recurrent gastric cancer after failure of first line chemotherapy with fluoropyrimidine +/- platinum.

    Drug: Paclitaxel

Interventions

  • Oral administration on day 1,8,15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent

    Also known as: DHP107

  • Premedication, IV infusion on day 1 of 3-week cycle until progression, unacceptable toxicity or withdrawal of informed concent

    Also known as: Taxol®

06

What researchers measure

Primary outcomes

  1. Progression Free Survival

    PFS is defined as the time From date of randomization until the date of first documented progression or death, assessed up to 24 months.

    Time frame: Participants will be followed until progression, an expected average of 4 months.

Secondary outcomes

  1. Overall Survival

    OS is defined as the time from the date of inclusion to the date of death, regardless of the cause of death.

    Time frame: Until 6 months after the last participant is enrolled, assessed up to 24 months.

  2. Overall Response Rate

    ORR is defined by Response Evaluation Criteria in Solid Tumors (RECIST) (v.1.1) criteria.

    Time frame: Participants will be followed every 6 weeks until progression, an expected average of 4 months.

07

Study locations

13 sites
  • Inje University Haeundae Paik Hospital
    Busan, 612-896, Korea, Republic of
  • Chonnam National University Hwasun Hospital
    Chungnam, 519-763, Korea, Republic of
  • Kyungpook National University Medical Center
    Daegu, 702-210, Korea, Republic of
  • National Cancer Center
    Goyang-si, 410-769, Korea, Republic of
  • Seoul National University Bundang Hospital
    Seongnam-si, Korea, Republic of
  • Yonsei University Severance Hospital
    Seoul, 120-752, Korea, Republic of
  • Samsung Medical Center
    Seoul, 135-710, Korea, Republic of
  • Yonsei University Gangnam Severance Hospital
    Seoul, 135-720, Korea, Republic of
  • Seoul St. Mary's Hospital
    Seoul, 137-701, Korea, Republic of
  • Asan Medical Center, University of Ulsan College of Medicine
    Seoul, 138-736, Korea, Republic of
  • Asan Medical Center
    Seoul, 138-736, Korea, Republic of
  • Korea University Guro Hospital
    Seoul, 152-703, Korea, Republic of
  • Ajou University Hospital
    Suwon, 443-380, Korea, Republic of
08

References and documents

Publications

  • Kang YK, Ryu MH, Park SH, Kim JG, Kim JW, Cho SH, Park YI, Park SR, Rha SY, Kang MJ, Cho JY, Kang SY, Roh SY, Ryoo BY, Nam BH, Jo YW, Yoon KE, Oh SC. Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy. Ann Oncol. 2018 May 1;29(5):1220-1226. doi: 10.1093/annonc/mdy055. PubMed 29438463 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2013
First posted
Apr 25, 2013
Start
Mar 2013
Primary completionActual
Aug 2015
CompletionActual
Aug 2015
Last update
Jul 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01839773
Lead sponsor
Daehwa Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Apr 25, 2013
Start date
Mar 2013
Primary completion
Aug 2015
Completion
Aug 2015
Last update
Jul 25, 2024

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paclitaxel

Start the discussion